Names that match “Act III Communications”
1,696 documents found
the trust is irrevocable and Mr. Garcia IJ is not a beneficiary. Mr. Garcia III is the sole
document investment trustees over Ernest Irrevocable 2004 Trust IIT House Oversight Committee — Epstein Estate Records (Nov 2025)
the trust is irrevocable and Mr. Garcia IJ is not a beneficiary. Mr. Garcia III is the sole
and four additional ALS ambulances typically Type III models allowing for
document Response Vehicles House Oversight Committee — Epstein Estate Records (Nov 2025)
and four additional ALS ambulances typically Type III models allowing for
a Class III medical device approved by FDA in 1993. The
document generation product was the FC1 Female Condom House Oversight Committee — Epstein Estate Records (Nov 2025)
a Class III medical device approved by FDA in 1993. The
To: Melanie Spincll iii i Zi
email IMAGES-007-HOUSE_OVERSIGHT_023355.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
miami ), commitments dividends, BRH TRA, shareholder agreements, bank loan
agreements. wills, construction, , contracts planning permits etc..employ rules. checking account
reconciliations, crediti cards. jewelry , cost basis ,( art stock etc.) foundations regs , brokerage accts...
From: Nicholas Rit iii
email IMAGES-011-HOUSE_OVERSIGHT_031787.txt May 29, 2019 House Oversight Committee — Epstein Estate Records (Nov 2025)
From: Nicholas Rit iii
Sent: 5/29/2019 2:14:44 PM
To: Jeffrey Epstein [[email protected]]
Importance: — High
Mueller statement at 1lam will be interesting - I think it's because of Michael wolff's new book and the
reference to a draft indictment- it probably will be helpf...
and (iii) markets continue to be sceptical of a 2016 MMAR
document allocations are historically elevated House Oversight Committee — Epstein Estate Records (Nov 2025)
and (iii) markets continue to be sceptical of a 2016 MMAR
On Sun, Mar 17, 2019 at 11:48 AM Larry Summers iii. wrote
document IMAGES-012-HOUSE_OVERSIGHT_033449.txt Mar 17, 2019 House Oversight Committee — Epstein Estate Records (Nov 2025)
… both have still not agreed the rules of the game. so difficult to play . you
have laid out - this is whati want. . but actually , how it would work , and what her freedoms are. could
HOUSE_OVERSIGHT_033449
and (iii) a “Marijuana Termination” SAR if the
document state law or implicates any Cole Memo priority House Oversight Committee — Epstein Estate Records (Nov 2025)
and (iii) a “Marijuana Termination” SAR if the
(ii) development (5) follows two years thereafter and (iii) development (6) occurs by 2027 and
document in 2023 House Oversight Committee — Epstein Estate Records (Nov 2025)
(ii) development (5) follows two years thereafter and (iii) development (6) occurs by 2027 and
(ii) the addition of states and (iii) same-store growth in existing states
document grades House Oversight Committee — Epstein Estate Records (Nov 2025)
(ii) the addition of states and (iii) same-store growth in existing states.
(iii) offer Partners the opportunity to exchange their Common LP Units
document the Initial Listing to the Partners House Oversight Committee — Epstein Estate Records (Nov 2025)
(iii) offer Partners the opportunity to exchange their Common LP Units
364 shares of k12 common stock at $1.60 per share and (iii) warrants to
document warrants to purchase 53 House Oversight Committee — Epstein Estate Records (Nov 2025)
364 shares of k12 common stock at $1.60 per share and (iii) warrants to
two Phase III trials in Lennox-Gastaut syndrome (LGS)
document Phase III trials in Dravet House Oversight Committee — Epstein Estate Records (Nov 2025)
two Phase III trials in Lennox-Gastaut syndrome (LGS)
and a Phase II/III trial in infantile spasms. The first
document III trial in tuberous sclerosis complex House Oversight Committee — Epstein Estate Records (Nov 2025)
and a Phase II/III trial in infantile spasms. The first
varies between different banks and (iii)
document likely impact from a more hawkish ECB House Oversight Committee — Epstein Estate Records (Nov 2025)
varies between different banks and (iii)